Zacks: BeyondSpring Inc. (BYSI) Receives Consensus Rating of “Strong Buy” from Brokerages
BeyondSpring Inc. (NASDAQ:BYSI) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy rating.
Brokerages have set a 12 month consensus price objective of $51.00 for the company and are predicting that the company will post ($0.69) earnings per share for the current quarter, according to Zacks. Zacks has also given BeyondSpring an industry rank of 108 out of 265 based on the ratings given to related companies.
Several research firms have recently weighed in on BYSI. Zacks Investment Research downgraded BeyondSpring from a “hold” rating to a “sell” rating in a report on Monday, July 3rd. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of BeyondSpring in a report on Monday, August 21st. Rodman & Renshaw boosted their target price on BeyondSpring from $43.00 to $50.00 and gave the company a “buy” rating in a report on Friday, July 14th. Finally, Maxim Group began coverage on BeyondSpring in a report on Tuesday, August 22nd. They issued a “buy” rating and a $52.00 target price for the company.
BeyondSpring (BYSI) opened at 32.50 on Tuesday. The stock has a 50 day moving average price of $37.28 and a 200-day moving average price of $35.29. The firm’s market capitalization is $742.43 million. BeyondSpring has a one year low of $16.55 and a one year high of $48.49.
An institutional investor recently bought a new position in BeyondSpring stock. Tanaka Capital Management Inc. purchased a new stake in BeyondSpring Inc. (NASDAQ:BYSI) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 21,322 shares of the company’s stock, valued at approximately $914,000. BeyondSpring accounts for about 2.1% of Tanaka Capital Management Inc.’s portfolio, making the stock its 16th largest position. Tanaka Capital Management Inc. owned 0.10% of BeyondSpring as of its most recent SEC filing. 1.23% of the stock is currently owned by hedge funds and other institutional investors.
BeyondSpring Company Profile
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with MarketBeat.com's FREE daily email newsletter.